Veradermics Inc.

New Haven-based Veradermics Inc. said Tuesday it has raised $766.8 million this year, giving the biotech company enough cash to fund its operations into 2030 as it advances a late-stage experimental hair-loss treatment.

Connecticut Innovations (CI), the state’s quasi-public venture capital arm based in New Haven, said Wednesday it invested approximately $6 million in 15 companies and venture funds during the third quarter of its fiscal year, which ended March 31.

Veradermics Inc., the New Haven drug developer working on an oral treatment for hair loss, raised $256.3 million from its initial public offering on Wednesday.

Veradermics Inc., the New Haven drug developer working on an oral treatment for hair loss, said it expects to raise about $181.8 million in its planned initial public offering.

Veradermics Inc., a New Haven-based biopharmaceutical startup developing an oral treatment for pattern hair loss, has filed for an initial public offering.

New Haven-based Veradermics raised $150M to advance its oral minoxidil pill for hair loss into Phase 3 trials. The biotech, founded by dermatologist Reid Waldman, is recruiting 1,500 patients for the study.

Veradermics Inc. announced it has begun enrolling women in a Phase 2/3 clinical trial of its experimental oral treatment for female pattern hair loss.

Veradermics Inc., a New Haven-based biopharmaceutical company, said Thursday it has closed a $150 million Series C financing round.